NewsBenzingaWedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1 Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1 Benzinga 2026.09.23 12:12 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Why Is Applied Digital Stock Surging on Monday?
